About this trial
The CONCRET-SARCOPA trial is a 12-week, double-blind, randomized controlled study designed to evaluate the efficacy of creatine HCl supplementation in older adults with sarcopenia. The trial investigates whether daily creatine HCl improves body composition, enhances functional muscle and cognitive performance, and favorably alters key blood biomarkers associated with muscle health and metabolic status. Additionally, the study assesses changes in tissue creatine levels using non-invasive and biochemical methods to clarify mechanistic responses to supplementation. Findings from this trial will provide critical evidence on the therapeutic potential of creatine HCl as a targeted nutritional strategy for managing sarcopenia in the geriatric population.
Eligibility criteria
Qualifiers
Age > 60 years
Low muscle strength by handgrip (SDOC criteria for sarcopenia): < 35.5 kg in men and < 20 kg in women
Sign free and informed consent
Demonstrate interest, conditions and availability to participate
Disqualifiers
Patients undergoing interventional treatment for sarcopenia
Physical amputation
Cognitive impairment (MSSE < 25)
Unwillingness to return for follow-up analysis
Trial design
Treatments tested in this trial
- Experimental 1
- Experimental 2